Merck, Inc.
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 808
- Registration Number
- NCT04700124
- Locations
- 🇯🇵
Gifu University Hospital ( Site 1513), Gifu, Japan
🇷🇺Volgograd Regional Uronephrological Center ( Site 0870), Volzhsky, Volgogradskaya Oblast, Russian Federation
🇺🇦Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965), Kharkiv, Kharkivska Oblast, Ukraine
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT04678505
- Locations
- 🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States
🇺🇸Prism Clinical Research, LLC ( Site 0002), Saint Paul, Minnesota, United States
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT04676412
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University ( Site 0113), Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital ( Site 0104), Changsha, Hunan, China
🇨🇳Anhui Provincial Hospital ( Site 0108), Hefei, Anhui, China
A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04676425
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Miami, Florida, United States
🇺🇸ProSciento Inc. ( Site 0002), Chula Vista, California, United States
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
- Conditions
- Invasive Fungal Infection
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04665037
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego ( Site 2101), San Diego, California, United States
🇺🇸Nicklaus Children's Hospital ( Site 2109), Miami, Florida, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 2104), Chicago, Illinois, United States
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT04663321
- Locations
- 🇺🇸
Atlanta Center for Medical Research ( Site 1022), Atlanta, Georgia, United States
🇺🇸Woodland International Research Group ( Site 1017), Little Rock, Arkansas, United States
🇺🇸Institute of Living ( Site 1061), Hartford, Connecticut, United States
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: PNEUMOVAX™23Biological: V116
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 102
- Registration Number
- NCT04665050
- Locations
- 🇯🇵
Souseikai Nishikumamoto Hospital ( Site 0202), Kumamoto, Japan
🇯🇵Souseikai PS Clinic ( Site 0201), Fukuoka, Japan
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
- Conditions
- Advanced/Metastatic Gastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 895
- Registration Number
- NCT04662710
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0003), Los Angeles, California, United States
🇦🇺Nepean Hospital ( Site 2305), Kingswood, New South Wales, Australia
🇺🇸Mount Sinai Hospital ( Site 0051), New York, New York, United States
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
- Conditions
- HIV Preexposure Prophylaxis
- Interventions
- Drug: FTC/TDFDrug: Placebo to FTC/TDFDrug: Placebo to FTC/TAFDrug: Placebo to ISL
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 494
- Registration Number
- NCT04652700
- Locations
- 🇺🇸
Howard Brown Health Center ( Site 0004), Chicago, Illinois, United States
🇿🇦Desmond Tutu HIV Foundation ( Site 0202), Cape Town, Western Cape, South Africa
🇺🇸Bridge HIV - San Francisco Department of Public Health ( Site 0003), San Francisco, California, United States
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
- Conditions
- HIV-IProphylaxisHuman Immunodeficiency Virus Type 1
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 730
- Registration Number
- NCT04644029
- Locations
- 🇺🇬
MU-JHU Care Limited-Clinic ( Site 0041), Kampala, Uganda
🇿🇦Madibeng Centre for Research ( Site 0019), Brits, North-West, South Africa
🇿🇦Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023), Johannesburg, Gauteng, South Africa